Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: A report on safety and immunogenicity

Journal of Immunotherapy

Volumn 27, Issue 6, 2004, Pages 442-451

  Guthmann, Marcelo D ^a   Bitton, Roberto J ^a   Carnero, Ariel J L ^a   Gabri, Mariano R ^b   Cinat, Gabriela ^a   Koliren, Leonardo ^c   Lewi, Daniel ^d   Fernandez, Luis Enrique ^e   Alonso, Daniel F ^b   Gómez, Daniel E ^b   Fainboim, Leonardo ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c HOSPITAL DURAND   (Argentina)

^d HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^e CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccines; Gangliosides; GM3; Melanoma

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GANGLIOSIDE GM3; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MONTANIDE ISA 51; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VERY SMALL SIZE PROTEOLIPOSOME;

ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; EDEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPOTENSION; IMMUNOGENICITY; MALE; MEDIASTINUM MASS; MELANOMA; MELANOMA CELL; NEISSERIA MENINGITIDIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SERUM; SIDE EFFECT; SOFT TISSUE TUMOR; TREATMENT OUTCOME; TUMOR BIOPSY; VITILIGO;

EID: 7444262837     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200411000-00004     Document Type: Article

References (38)

1. Wolchok JD, Livingston PO, Houghton AN. Vaccines and other adjuvant therapies for melanoma. Hematol Oncol Clin North Am. 1998;12:835-848.
2. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
3. Tsuchida T, Saxton RE, Morton DL, et al. Gangliosides of human melanoma. J Natl Cancer Inst. 1987;78:45-54.
4. Tsuchida T, Ravindranath MH, Saxton RE, et al. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res. 1987;47:1278-1281.
5. Hamilton WB, Helling F, Lloyd KO, et al. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer. 1993;53:566-573.
6. Kiura K, Watarai S, Ueoka H, et al. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res. 1998;18:2957-2960.
7. Livingston PO, Ritter G, Calves MJ. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother. 1989;29:179-184.
8. Tai T, Cahan LD, Tsuchida T, et al. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer. 1985;35:607-612.
9. Takahashi T, Johnson TD, Nishinaka Y, et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol. 1999;112:205-209.
10. Ragupathi G, Meyers M, Adluri S, et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer. 2000;85:659-666.
11. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214-5220.
12. Dohi T, Nores G, Hakomori S. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res. 1988;48:5680-5685.
13. Tietze LF, Keim H, Janssen CO, et al. Synthesis of a novel ether-bridged GM3-lactone analogue as a target for an antibody-based cancer therapy. Chemistry. 2000;6:2801-2808.
14. Bitton RJ, Guthmann MD, Gabri MR, et al. Cancer vaccines: an update with special focus on ganglioside antigens. Oncol Rep. 2002;9:267-276.
15. Estevez F, Carr A, Solorzano L, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18:190-197.
16. Carr A, Mazorra Z, Alonso DF, et al. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 2001;11:219-227.
17. Alonso DF, Gabri MR, Guthmann MD, et al. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol. 1999;15:59-66.
18. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
19. Vazquez AM, Alfonso M, Lanne B, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma. 1995;14:551-556.
20. Gabrielsson S, Söderlund A, Paulie S, et al. Increased frequencies of allergen-induced interleukin-13-producing cells in atopic individuals during the pollen season. Scand J Immunol. 1998;48:429-435.
21. Ravindranath MH, Ravindranath RM, Morton DL, et al. Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J Immunol Methods. 1994;169:257-272.
22. Reizenstein E, Hallander HO, Blackwelder WC, et al. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods. 1995;183:279-290.
23. Carr A, Rodriguez E, Arango MC, et al. Immunotherapy of advanced breast cancer with a heterphilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21:1015-1021.
24. Nores GA, Dohi T, Taniguchi M, et al. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol. 1987;139:3171-3176.
25. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036-1044.
26. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301-305.
27. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2:85-95.
28. Gelderman KA, Tomlinson S, Ross GD, et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25:158-164.
29. Zhang H, Zhang S, Cheung NK, et al. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998;58:2844-2849.
30. Kirkwood JM, Mascari RA, Edington HD, et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000;88:2693-2702.
31. Irie RF, Ollila DW, O'Day S, et al. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother. 2004;53:110-117.
32. Steet R, Alizadeh M, Melancon P, et al. 3′-Azidothymidine significantly alters glycosphingolipid synthesis in melanoma cells and decreases the shedding of gangliosides. Glycoconj J. 1999;16:237-245.
33. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol. 1999;163:3718-3726.
34. Kanda N. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun. 1999;256:41-44.
35. Péguet-Navarro J, Sportouch M, Popa I, et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol. 2003;170:3488-3494.
36. Péguet-Navarro J, Moulon C, Caux C, et al. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol. 1994;24:884-891.
37. Shamshiev A, Donda A, Carena I, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol. 1999;29:1667-1675.
38. Benlagha K, Weiss A, Beavis A, et al. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med. 2000;191:1895-1903.